Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | UGCG | Q16739 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 7/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783159 | 0.86 | NR1I2 (0.49) | NR1I2UGCGPARP1PARP2F10 | |
| SCHEMBL5784301 | 0.85 | F10 (0.55) | NR1I2UGCGF10ALDH1A1HPGD | |
| SCHEMBL13950131 | 0.84 | NR1I2 (0.47) | NR1I2UGCGPARP1PARP2F10 | |
| SCHEMBL6404781 | 0.83 | NR1I2 (0.46) | NR1I2UGCGPARP1PARP2F10 | |
| SCHEMBL6404809 | 0.83 | NR1I2 (0.46) | NR1I2UGCGPARP1PARP2F10 | |
| SCHEMBL5784790 | 0.83 | NR1I2 (0.46) | NR1I2UGCGPARP1PARP2F10 | |
| SCHEMBL6404923 | 0.82 | ACHE (0.43) | NR1I2UGCGF10ALDH1A1HPGD | |
| SCHEMBL5784441 | 0.82 | ACHE (0.43) | NR1I2UGCGF10ALDH1A1HPGD | |
| SCHEMBL4309505 | 0.80 | PARP1 (0.44) | NR1I2UGCGPARP1F10ALDH1A1 | |
| SCHEMBL5782990 | 0.80 | F10 (0.55) | NR1I2UGCGPARP1F10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408962-B1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-6933295-B2 | Substituted isoindoles and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-08-23 | — | — | US | disclosed |
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-06 | — | — | US | disclosed |
| EP-1408962-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003007942-A1 | SUBSTITUTED ISOINDOLES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004207-A1 | Nitrogen compounds such as N-(2-{4-[2-Amino-2-(hydroxyimino)ethyl]benzyl}-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl)-5-chloro-2-thiophenecarboxamide, used as blood-coagulation factor Xa antogonists for prophylaxis of cardiovascular disorders | F2, SERPINC1, F11 | NR1I2 569/4885UGCG 2124/4885PARP1 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.